Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.
Read original at benzingaStocks · News reference
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32
Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 6:07 PM
- Checked
- Aug 14, 2026, 6:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
Read original at benzingaZenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.08) by 63.89 percent. This is a 41.6 percent decrease over losses of $(1.25) per share from
Read original at benzinga